Mucormycosis: An opportunistic pathogen during COVID-19

Area of Science:

• Mycology
• Infectious Diseases
• Epidemiology

Background:

• The COVID-19 pandemic continues to surge globally, with limited treatment options.
• Supportive care, including steroids, is crucial for managing severe COVID-19.
• Secondary infections like mucormycosis are increasingly observed in COVID-19 patients.

Purpose of the Study:

• To review mucormycosis and its association with COVID-19.
• To understand the mechanism, influencing factors, and challenges of this fungal infection.
• To highlight the importance of early diagnosis and treatment.

Main Methods:

• Literature review of recent studies on COVID-19 and mucormycosis.
• Analysis of the role of steroids and diabetes in COVID-19 patients with mucormycosis.
• Discussion of the pathophysiology and risk factors.

Main Results:

• COVID-19 patients, particularly those with diabetes on steroids, are at higher risk for mucormycosis.
• Mucormycosis is a rapidly spreading opportunistic fungal infection.
• Prompt diagnosis and treatment are essential to reduce mortality and morbidity.

Conclusions:

• There is an alarming increase in mucormycosis among COVID-19 patients.
• Understanding the interplay between COVID-19, immunosuppression, and fungal infections is critical.
• Early identification and intervention strategies are vital for combating mucormycosis in the pandemic.